Emerald Health Therapeutics, Inc. (Emerald) announced that, further to its news releases dated April 17, 2018 and November 19, 2018, it has closed its 51:49 joint venture (Joint Venture) with Emerald Health Bioceuticals (EHB), called Emerald Health Naturals (EHN). Emerald has invested $5,000,000 for 51% equity ownership of EHN. EHB has granted EHN the exclusive Canadian distribution rights to EHB’s product line in exchange for 49% equity ownership of EHN. EHB’s product line consists of nutritional supplements that use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system.